Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Anti-LAG-3 with or without anti-PD-1 in recurrent glioblastoma: a phase 1 trial.

Nature medicine·2026

Same author

Epidemiology of eyelid disorders in an elderly population: Tehran Geriatric Eye Study.

BMC ophthalmology·2026

Same author

Measuring children's spatial accessibility to urban park green spaces.

Scientific reports·2026

Same author

Immune-Mediated IgA Nephropathy Induced by PD-1 Blockade in Extranodal NK/T-Cell Lymphoma.

International medical case reports journal·2026

Same author

Can a self-regulated flipped classroom improve creative performance? Evidence from a randomized controlled trial.

Frontiers in psychology·2026

Same author

DCM-ML: An Electroencephalography-based Classifier for Early Diagnosis of Schizophrenia Based on Dynamic Connectivity Matrices and Machine Learning Algorithms.

Basic and clinical neuroscience·2026

Search research articles

Related Experiment Video

Updated: Sep 25, 2025

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

Cognitive function after concurrent temozolomide-based chemoradiation therapy in low-grade gliomas.

Deborah Y Park¹, Martin C Tom², Yanwen Chen³

¹Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland Clinic, Cleveland, OH, USA.

Journal of Neuro-Oncology

|April 29, 2022

Summary

Neurocognitive function in low-grade glioma patients remained stable after chemoradiation therapy with temozolomide. This study evaluated cognitive changes over two years, finding no significant decline in most measures.

Keywords:

Chemoradiation Cognitive function Low grade glioma Neurocognitive testing Temozolomide

More Related Videos

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

Published on: April 16, 2019

Quantifying Cognitive Decrements Caused by Cranial Radiotherapy

Quantifying Cognitive Decrements Caused by Cranial Radiotherapy

Published on: October 18, 2011

Related Experiment Videos

Last Updated: Sep 25, 2025

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

Published on: April 16, 2019

Quantifying Cognitive Decrements Caused by Cranial Radiotherapy

Quantifying Cognitive Decrements Caused by Cranial Radiotherapy

Published on: October 18, 2011

Area of Science:

Neuro-oncology
Cognitive Neuroscience
Radiation Oncology

Background:

Low-grade gliomas (LGG) are primary brain tumors.
Temozolomide-based chemoradiation therapy (RT+TMZ) is a standard treatment for LGG.
Understanding the impact of RT+TMZ on neurocognitive function is crucial for patient quality of life.

Purpose of the Study:

To evaluate the effects of concurrent temozolomide-based chemoradiation therapy on neurocognitive function in adult patients with low-grade glioma.
To assess changes in cognitive performance over time following RT+TMZ treatment.

Main Methods:

Prospective evaluation of adult LGG patients treated with postoperative RT+TMZ.
Comprehensive psychometric testing at baseline and at various intervals post-treatment.
Analysis of baseline cognitive performance by demographic and clinical factors, including IDH mutation and 1p/19q codeletion status.

Main Results:

Thirty-seven LGG patients underwent baseline neurocognitive evaluation.
Superior baseline verbal memory (HVLT) was observed in patients older than 40 years and those with over 16 years of education.
No statistically significant differences in overall neurocognitive performance were found before and after RT+TMZ, except for HVLT Discrimination.

Conclusions:

Neurocognitive function remained stable up to two years post-treatment with RT+TMZ in LGG patients.
RT+TMZ did not lead to significant neurocognitive decline in this cohort.
Further analysis of RTOG 0424 will provide specific neurocognitive outcomes for high-risk LGG patients.